This book aims to introduce the core model to those with a basic knowledge of axiomatic set theory. The covering lemma for K is the main technical result but other applications are also considered.

The Core Model: A Collaborative Paradigm for the Pharmaceutical Industry and Global Health Care develops the innovative core model, an organizational research and design paradigm and economic theory that proposes a collaborative approach to resolving global health issues and improving the productivity of drug development. The model proposes that scientific collaboration does not occur in an unstructured manner, but actually takes place within a highly structured order where knowledge is transferred, integrated and finally translated into commercial products. An understanding of this model will help solve the global pharmaceutical industry ́s productivity problems and address important global health care and economic issues. This book is useful to researchers, advanced students, regulators, and management in pharmaceutical industries, as well as healthcare professionals, those working in health economics, and those interested in scientific innovation processes. - Explores the current state-of-the-art in the pharmaceutical industry and the global healthcare sector - Includes insights from world-leading figures in the pharmaceutical industry, healthcare sector, federal funding agencies, regulatory bodies, investment sector, entrepreneurship, intellectual property law, philanthropic organizations, and advocacy groups - Develops in-depth, original concepts, which have important implications in the understanding of, and search for, potential solutions to the world ́s health care crisis

Suitable for graduate students and researchers in set theory, this volume develops a method for constructing core models that have Woodin cardinals.

In this key title, Lester Telser, the world's core theorist, explores several distinct areas to skilfully bring the ideas of core theory to bear on a range of issues within economics - with particular emphasis on supply and demand and the way markets function.

People make use of software applications in their activities, applying them as tools in carrying out tasks. That this use should be good for people--easy, effective, efficient, and enjoyable--is a principal goal of design. In this book, we present the notion of Conceptual Models, and argue that Conceptual Models are core to achieving good design. From years of helping companies create software applications, we have come to believe that building applications without Conceptual Models is just asking for designs that will be confusing and difficult to learn, remember, and use. We show how Conceptual Models are the central link between the elements involved in application use: people's tasks (task domains), the use of tools to perform the tasks, the conceptual structure of those tools, the presentation of the conceptual model (i.e., the user interface), the language used to describe it, its implementation, and the learning that people must do to use the application. We further show that putting a Conceptual Model at the center of the design and development process can pay rich dividends: designs that are simpler and mesh better with users' tasks, avoidance of unnecessary features, easier documentation, faster development, improved customer uptake, and decreased need for training and customer support. Table of Contents: Using Tools / Start with the Conceptual Model / Definition / Structure / Example / Essential Modeling / Optional Modeling / Process / Value / Epilogue

bull; Shows how EMF unifies three important technologies: Java, XML, and UML bull; Provides a comprehensive overview of the EMF classes including a complete quick reference for all the classes and methods in the EMF 1.1 API bull; Includes examples of many common framework customizations and programming techniques

This first comprehensive survey to cover all pharmaceutically relevant topics provides a comprehensive introduction to this novel and revolutionary tool, presenting both concepts and application examples of biosimulated cells, organs and organisms. Following an introduction to the role of biosimulation in drug development, the authors go on to discuss the simulation of cells and tissues, as well as simulating drug action and effect. A further section is devoted to simulating networks and populations, and the whole is rounded off by a look at the potential for biosimulation in industrial drug development and for regulatory decisions. Part of the authors are members of the BioSim Network of Excellence that encompasses more than 40 academic institutions, pharmaceutical companies and regulatory authorities dealing with drug development; other contributors come from industry, resulting in a cross-disciplinary expert reference.

The core model, K, is a generalization of Gödel's constructible universe of set theory; K is used to produce 'fine structural' results of a less restrictive kind. This book aims to introduce the core model to those with a basic knowledge of axiomatic set theory. The covering lemma for K is the main technical result but other applications are also considered. The author gives a full exposition of general fine structure and of iterated ultrapowers and concludes the work with a short section on the difficulties encountered in constructing more general core models using 'extenders'.

Social Mobility in Europe is the most comprehensive study to date of trends in intergenerational social mobility. It uses data from 11 European countries covering the last 30 years of the twentieth century to analyze differences between countries and changes through time. The findings call into question several long-standing views about social mobility. We find a growing similarity between countries in their class structures and rates of absolute mobility: in other words, the countries of Europe are now more alike in their flows between class origins and destinations than they were thirty years ago. However, differences between countries in social fluidity (that is, the relative chances, between people of different class origins, of being found in given class destinations) show no reduction and so there is no evidence supporting theories of modernization which predict such convergence. Our results also contradict the long-standing Featherman Jones Hauser hypothesis of a basic similarity in social fluidity in all industrial societies 'with a market economy and a nuclear family system'. There are considerable differences between countries like Israel and Sweden, where societal openness is very marked, and Italy, France, and Germany, where social fluidity rates are low. Similarly, there is a substantial difference between, for example, the Netherlands in the 1970s (which was quite closed) and in the 1990s, when it ranks among the most open societies. Mobility tables reflect many underlying processes and this makes it difficult to explain mobility and fluidity or to provide policy prescriptions. Nevertheless, those countries in which fluidity increased over the last decades of the twentieth century had not only succeeded in reducing class inequalities in educational attainment but had also restricted the degree to which, among people with the same level of education, class background affected their chances of gaining access to better class destinations.